Jasper Therapeutics, Inc. Banner Image

Jasper Therapeutics, Inc.

  • Ticker JSPR
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Jasper Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in Redwood City, California
Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FAMore) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in over 130 dosed subjects and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD. In addition, briquilimab is being advanced as a transformational non-genotoxic conditioning agent for gene therapy.
5.0 / 5.0 (2)

Jasper Therapeutics, Inc. reports have an aggregate usefulness score of 5.0 based on 2 reviews.

Jasper Therapeutics, Inc.

Most Recent Annual Report

Jasper Therapeutics, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Jasper Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!